Differentiation of rat multipotent adult progenitor cells to functional hepatocyte-like cells by mimicking embryonic liver development by Roelandt, Philip et al.
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IntroDuctIon
Primary hepatocytes are currently used for a number of applica-
tions: drug development, drug metabolism and drug toxicity stud-
ies (absorption, distribution, metabolism, excretion and toxicity 
studies, also known as ADMET studies), studies of hepatitis virus 
infection and creation of antiviral drugs, and investigations of new 
therapies for liver diseases, such as development of artificial liver 
devices and cell transplantation. However, hepatocytes isolated 
from human or animal liver can only be maintained in culture for 
a limited time, as they rapidly lose their phenotypic and functional 
characteristics. Stem or progenitor-derived functional hepatocytes 
have been suggested as a good alternative for primary hepatocytes, 
and the optimization of hepatic differentiation protocols is consid-
ered to be crucial for the further expansion of hepatocyte-like cells 
for applications in ADMET and therapeutic indications.
Multipotent adult progenitor cells (MAPCs)
Rodent multipotent adult progenitor cells (MAPCs) were first 
isolated in 2002 from the adherent fraction of the bone marrow 
(see Box 1 for a brief summary of an updated isolation protocol1). 
Cultured rat (r)MAPCs have extensive proliferative ( > 100 popu-
lation doublings) and multilineage differentiation capacity at the 
clonal level2,3. rMAPC clones express levels of Oct4 between 10 and 
60% of embryonic stem cells (ESCs). Phenotypically, rMAPCs are 
CD90 and MHC class II negative, have low levels of MHC class I and 
CD44 and are CD31 positive. The transcriptome analysis shows 
that rMAPCs express several ESC-associated transcripts (ECATs)4, 
including Oct4 and Rex1, as well as nMyc, Lin28 and Klf4, known to 
have a role in the generation of iPSC, but do not express other ECATs, 
including Nanog, Sox2 or the ESC gene Esrrb. Moreover, rMAPCs 
also express genes characteristic of primitive or visceral endoderm, 
such as XEN cells5 or XEN-P cells6, such as Sox7, Sox17, Gata4, Gata6, 
Foxa2 and Hnf1β3.
Since the description of MAPC in 2002 (ref. 7), different cell 
types with similar extended differentiation potency have been 
isolated from human or rodent tissues, including unrestricted 
somatic stem cells (USSCs)8, human bone marrow–derived 
multipotent stem cells (hBMSCs)9, marrow-isolated adult multilin-
eage-inducible (MIAMI) cells10, amniotic fluid-derived stem (AFS) 
cells11, human fetal liver multipotent progenitor cells (hFLMPCs)12, 
very small embryonic-like cells13, pre-MSCs14, human multipotent 
adult stem cells (MASCs)15 and others. Similar to MAPCs, many 
of these cell populations display extensive expansion capacity 
and unexpected broad differentiation ability, as they can generate 
differentiated progeny beyond the boundaries of the tissue from 
which they were isolated. Some of the cell types described above also 
express Oct4, Nanog and Sox2, and, similar to ESCs, can generate cell 
types with the characteristics of cells from all three germ layers.
Hepatic differentiation of adult stem cells
MAPCs, pre-MSCs and MASCs generated from bone marrow14–16, 
USSCs generated from UCB17, AFS generated from amniotic fluid18, 
and hFLMPCs generated from fetal liver12 have been induced to 
differentiate into cells with hepatocyte-like cell characteristics 
in vitro. Although these cell types have a number of characteris-
tics in common, the isolation and culture procedure, phenotype 
and potency are different. In 2002, we demonstrated that rMAPC 
lines could generate hepatocyte-like cells after a simple exposure 
to hepatocyte growth factor (HGF) and fibroblast growth fac-
tor (FGF)4, even though the different steps by which MAPCs 
acquired transcripts, proteins and functional attributes of hepa-
tocytes were not described16. As the isolation techniques used for 
rMAPC isolation before 2002 differ from the ones we use now 
(see Box 1), the phenotype of rMAPCs used in the 2002 studies 
differed from that of the present rMAPC lines. Most notably, 
Oct4 mRNA levels were  > 100-fold lower and 2002-undifferenti-
ated rMAPCs did not express Foxa2, Gata4 or Gata6. When we 
applied the cytokine mixture described previously16,19 to induce 
differentiation of the more recently isolated Oct4high rMAPC lines, 
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Differentiation of stem cells to hepatocytes has industrial applications, as well as the potential to develop new therapeutic 
strategies for liver disease. the protocol described here, sequentially using cytokines that are known to have a role in liver embryonic 
development, efficiently differentiates rat multipotent adult progenitor cells (rMapcs) to hepatocyte-like cells by directing them 
through defined embryonic intermediates, namely, primitive streak/mesendoderm/definitive endoderm, hepatoblast and hepatocyte-
like phenotype. after 20 days, the final differentiated multipotent adult progenitor cell progeny is a mixture of cells, comprising 
cells with the characteristics of hepatoblasts and a smaller cell fraction with the morphological and phenotypical features of mature 
hepatocytes, as well as other mesodermal cells and some persistent undifferentiated rMapcs. a detailed functional characterization 
of the stem cell progeny is also described; this should be used to confirm that differentiated cells display the functional 
characteristics of mature hepatocytes, including albumin secretion, glycogen storage and several detoxifying functions such as urea 
production, bilirubin conjugation, glutathione S-transferase activity and cytochrome activity.
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hepatic genes were minimally induced. This led us to re-evaluate 
the culture conditions for liver differentiation.
The 20-day differentiation protocol described here is modeled 
on liver embryonic development (Fig. 1). To mimic Nodal/Cripto 
signaling and the canonical β-catenin activity involved in primi-
tive streak (PS) and definitive endoderm (DE) formation, cells 
were first treated for 6 days with Activin-A and Wnt3a, respec-
tively. Cytokines produced by the cardiac mesenchyme and the 
septum transversum mesenchyme to induce formation of hepatic 
endoderm from anterior endoderm were mimicked in vitro by 
the stimulation of cells with BMP4 and FGF2 for 4 d. A combi-
nation of FGFs (FGF1, FGF4 and FGF8) was used to mimic the 
growth factors that induce liver bud growth (4 d), and finally 
hepatocyte growth factor (HGF) and Follistatin were used to 
enhance the maturation of generated hepatoblasts into hepato-
cyte-like cells (6 days). The main difference between this protocol 
and the previously described protocol is the sequential exposure 
based on liver embryogenesis. Both cytokines used in the previ-
ous protocol (FGF4 and HGF) are incorporated into the current 
protocol, but are only used from day 10 onward, after two initial 
steps aimed at mimicking gastrulation and hepatic endoderm 
formation.
Evaluation of the success of the protocol
To monitor and evaluate the protocol efficiency, RT-qPCR and 
immunocytochemistry can be performed. A list of key genes to be 
evaluated is presented in Box 2, while the primer sequences we have 
successfully used are listed in Table 1. As a housekeeping gene, we 
have used Gapdh. We used the Qiagen RNeasy kit for RNA isola-
tion as per the manufacturer’s instructions, but alternative methods 
can be used. As positive controls for RT-qPCR, RNA from rat 
fetal liver at E15 and isolated adult rat hepatocytes are suitable. 
For immunocytochemistry, a list of possible combinations of 
antibodies for staining at different stages is presented in 
Box 2, whereas the antibodies, isotypes and fixatives we use are 
listed in Table 2.
As functional analysis, we chose a combination of secretion 
(albumin, urea), storage (glycogen) and detoxification capacity 
(cytochrome P450, glutathione S-transferase (GST), bilirubin con-
jugation). Albumin secretion is detectable from day 14 onward. 
Spontaneous urea production can already be found from day 6, but 
urea production in response to ammonia (urea cycle) is detectable 
from day 10, becoming maximal by day 20. Many substrates are 
conjugated to GSH by GST, for example, 1-chloro-2,4-dinitroben-
zene (CDNB). Therefore, the formation of GSH-CDNB is used as 
a quantitative assay to measure total GST activity. Subtypes of GST 
can be analyzed as well by using ethacrynic acid to measure fetal 
GSTπ activity and di-chloro-nitrobenzene for more mature GSTµ 
activity (protocol not shown).
Experimental design
The differentiation capacity of rMAPCs is unaffected by the passage 
number (no differences were seen for differentiations carried 
out between passages 17 and 35, equivalent to  > 100 population 
 Box 1 | ISoLATIoN oF RAT MULTIPoTENT ADULT PRoGENIToR CELLS FRoM 
BoNE MARRoW 
Bone marrow aspiration from E18 or 4-week-old rats:
(i)  Flush tibiae and femur with 15 ml of PBS containing 2% FBS under sterile conditions. Pass the flushed liquid through a 23-gauge 
needle.
(ii) Incubate the flushed bones for 30 min with PBS containing 0.2% collagenase and 0.02% DNase at 37 °C.
(iii) Filter both cell suspensions with a 40-µM cell strainer and centrifuge at 600g for 6 min at room temperature (20 °C).
(iv) Plate the cells in fibronectin-coated wells at 106 cells cm − 2 in 2-ml MAPC expansion medium (table 3).
High-density culture of cells for 1 month:
(v) For the first week of culturing, add 1 ml of medium every other day.
(vi) For the second week of culturing, change half of the medium every other day.
(vii) For the third and fourth weeks of culturing, trypsinize 1–2 times a week and replate at 80% confluence.
Column depletion of CD45 + cells with MACS microbeads:
(viii) After 4 weeks, trypsinize the cells, centrifuge and count. Label the cells with anti-rat CD45-PE antibody and anti-PE microbeads.
(ix) Run 3–5 × 106 cells through a 23–25-gauge needle through the MACS column at the rate of one drop every 4–5 s.
Subcloning, culture and screening for potential MAPC clones:
(x) Plate the eluted cells at five cells per well in a 96-well plate coated with fibronectin.
(xi) Change half of the medium every other day for 2 weeks.
(xii) After the second week, trypsinize colonies of 30–50 cells and expand them at low density without cell-to-cell contact.
(xiii) Maintain the cells at low density until small clusters of spindle/triangular small cells appear.
(xiv)  Expand newly formed clusters at 300 cells cm − 2. Detection of cells with MAPC phenotype may require between 2–10 weeks of 
culture.
(xv) Screen the clones for Oct4 by RT-qPCR or staining.
Adapted from Subramanian et al.1.
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Figure 1 | Overview of the liver differentiation protocol.
©
20
10
 N
at
ur
e 
A
m
er
ic
a,
 
In
c.
 
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
protocol
1326 | VOL.5 NO.7 | 2010 | nature protocols
doublings). rMAPCs with higher passage number do accumulate 
more genetic abnormalities; therefore, most of the cell cultures 
should be terminated around passage numbers 35–40.
Using the protocol described here, rMAPCs can be efficiently 
differentiated into PS/mesendoderm (ME)/DE, followed by the 
acquisition of a hepatoblast phenotype and finally the acquisition 
of mature hepatocyte characteristics. Freshly isolated rat hepa-
tocytes should be used as positive control for functional assays. 
Alternatively, immortalized cell lines (such as HepG2) can be used, 
bearing in mind that gene expression and functionality may differ 
from primary hepatocytes. As negative control, undifferentiated 
rMAPCs (day 0) can be used.
Hepatocyte differentiation from rMAPCs as described here 
is still in an experimental phase and the impurity of the final 
progeny makes them not yet suitable for toxicological or pre-
clinical studies. However, ongoing studies to scale the current 
protocols and to purify cells with mature hepatocyte features from 
the mixed progeny generated using the current protocol may ulti-
mately yield rMAPC hepatocyte progeny with mature functional 
characteristics similar to those of hepatocytes (metabolization 
of ammonia to urea, inducible cytochrome activity, bilirubin 
conjugation), which may be used for in vitro screening purposes 
including ADMET studies.
Conclusion
A large number of protocols have been described to differenti-
ate various types of mesenchymal stem cells into hepatocyte- 
like cells20–22. In most of these protocols, a sequential exposure or 
a combination of HGF, FGF and Oncostatin M is used. Obviously, 
the main focus of these protocols is the generation of hepato-
cytes, but only little emphasis to developmental milestones such 
as gastrulation has been paid. Because of the numerous differences 
between the protocols and the starting cell populations, it is nearly 
impossible to distinguish which protocol is the best or the most 
efficient. Besides the generation of functional hepatocyte-like cells, 
the main benefit of the protocol described here is that it also creates 
a model to study the early steps of liver embryogenesis. We have not 
yet determined whether the protocol described here also induces 
differentiation of MSCs or more primitive cells such as MIAMI, 
MASCs, BMSCs, USSCs and pre-MSCs among others into hepa-
tocyte-like cells. However, we did demonstrate that, with minimal 
changes, the protocol that supports rMAPC differentiation into 
hepatocyte-like cells can also be applied for hepatic differentiation 
of pluripotent cells, such as human and mouse embryonic and 
induced pluripotent stem cells, suggesting that cells susceptible to 
hepatocyte differentiation using the protocol described here should 
have (near)pluripotent features.
 Box 2 | REAL-TIME RT-qPCR ANALYSIS oF TRANSCRIPTS 
(Items in boldface type are detailed in Fig. 3.)
Undifferentiated MAPCs: Oct4, Foxa2, Sox7, Sox17
Primitive streak/mesendoderm: Eomes, Mixl1, Brachyury, Gsc, E-cadherin
Definitive endoderm: Hex, Mixl1, Cxcr4, Tm4sf2, Lhx1, Gsc, Sox17, E-cadherin
Hepatoblasts: Afp, Ttr, Krt19, Alb
Hepatocytes: Alb, Aat, Tat, G6pc, Adh1C, ApoF, Mrp2, Cps-1, Arg-1, Pepck, Cx32, HepPar1, To, Cyp2b6, Cyp1a2, Cyp7a1, Bsep, GlyS, 
Factor V
Liver-enriched transcription factors: Hnf4α, Hnf1α, Hnf6, Prox1, Cebpα, Cebpβ
Adapted from Sancho-Bru et al.28.
table 1 | Primers.
Genes Forward sequence reverse sequence
Aat 5′-CAAACAAGGTCAGCCATTCTC-3′ 5′-CAGCATCATTGTTGAAGACCC-3′
Afp 5′-ACCTGACAGGGAAGATGGTG-3′ 5′-GCAGTGGTTGATACCGGAGT-3′
Alb 5′-TCTGCACACTCCCAGACAAG-3′ 5′-AGTCACCCATCACCGTCTTC-3′
Cxcr4 5′-GGATGGTGGTGTTCCAGTTC-3′ 5′-TCCCCACGTAATACGGTAGC-3′
Cyp1a2 5′-GTCCAGGAACACTATCAAGAC-3′ 5′-ACTGTTTCAAATCCAGCTCC-3′
Factor V 5′-CAATGCCAGATGTAACAGTC-3′ 5′-TGTCAATATAAGCCTGCATCC-3′
G6pc 5′-GATTCCGGTGCTTGAATGTC-3′ 5′-AGGTGATGAGACAGTACCTC-3′
Gapdh TaqMan Rodent GAPDh control reagents (Applied Biosystems, cat. no. 4308313)
Gsc 5′-CCCGGTTCTGTACTGGTGTC-3′ 5′-CCCACGTCTGGGTACTTTGT-3′
Krt19 5′-CCACACTACGCAGATCCAGA-3′ 5′-ATGCTGAGCTGAGACTGCAA-3′
Mixl1 5′-GGGAAGATTTCCTCCATCGT-3′ 5′-CTGAGAACCAGATGTACAGAC-3′
Tat 5′-GGAAGCTAAGGATGTCATTCTG-3′ 5′-GACCTCAATTCCCATAGACTC-3′
Tm4sf2 5′-CTGAAACTGTATGCCATGTTCC-3′ 5′-ATCTTTGCCGTTGTAGTTCTG-3′
Ttr 5′-CAGCAGTGGTGCTGTAGGAGTA-3′ 5′-GGGTAGAACTGGACACCAAATC-3′
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MaterIals
REAGENTS
Ammonium bicarbonate (NH
4
HCO
3
) (Sigma, cat. no. 09830), Step 22,  
option C only
Anthrone (Sigma, cat. no. A-1631), Step 22, option B only
Anti-PE MicroBeads (Miltenyi Biotec, cat. no. 130-048-801)
Bilirubin (Sigma, cat. no. B4126)
BSA (Sigma, cat. no. A9418)
Cell strainer with 40-µm nylon mesh (BD Biosciences, cat. no. 352340)
Chloroform for HPLC (LabScan, cat. no. PLC05___X) Step 22, option F 
only ! cautIon Irritating, danger of serious health damage by prolonged 
exposure through inhalation. Use in a well-ventilated area.
Collagenase D (Roche, cat. no. 11-088-858-001)
Cytokines (R&D Systems): Activin-A (338-AC), BMP4 (314-BP), EGF 
(2028-3G), FGF1 (232-FA), FGF2 (233-FB), FGF4 (235-F4), FGF8b  
(423-F8), Follistatin-288 (769-FS), HGF (294-HGN), PDGF-BB (220-BB) 
and Wnt3a (1324-WN)
Dexamethasone (Sigma, cat. no. D2915)
DMEM-low glucose (Gibco, cat. no. 31885)
•
•
•
•
•
•
•
•
•
•
•
DNase (Sigma, cat. no. D-4263)
ELISA Starter Accessory Kit (Bethyl, cat. no. E101-122), Step 22,  
option A only
Fibronectin (Sigma, cat. no. F-0635)
Fetal bovine serum (HyClone, cat. no. CH30160.03)
Glutathione (GSH) (MP Biomedicals, cat. no. 02101814), Step 22, option E only
Glycogen (Sigma, cat. no. G-0885), Step 22, option B only
Growth factor-reduced Matrigel (BD Biosciences, cat. no. 354230)
Insulin–transferrin–selenium liquid medium supplement (Sigma,  
cat. no. I-3146)
Leukemia inhibitory factor (107 units ml − 1) (Chemicon, cat. no. ESG-1107)
Linoleic acid–BSA (LA-BSA, 0.845 mg ml − 1 LA, 100 mg ml − 1 BSA) (Sigma, 
cat. no. L-9530)
MACS separation CS column (Miltenyi Biotec, cat. no. 130-041-305)
MCDB 201 medium with trace elements, l-glutamine and 30 mM HEPES 
(MCDB; Sigma, cat. no. M-6770)
Methanol for HPLC (VWR BPH Prolabo, cat. no. 20837.320), Step 22,  
option F only
•
•
•
•
•
•
•
•
•
•
•
•
•
table 2 | Antibodies.
company catalog no. Dilution Isotype
Primary antibodies
 Oct3/4 (N19) Santa Cruz Biotech SC8628 1:1,000 Goat IgG
 Sox7 R&D Systems AF2766 1:20 Goat IgG
 Sox17 R&D Systems MAB 1924 1:300 Mouse IgG3
 Foxa2 Santa Cruz Biotech SC6554 1:200 Goat IgG
 Alb Dako A0001 1:8,000 Rabbit IgG
 Afp R&D Systems MAB 1368 1:4,000 Mouse IgG1
 Krt18 (N16) Santa Cruz Biotech SC31700 1:250 Goat IgG
 Pepck (H-300) Santa Cruz Biotech SC32879 1:200 Rabbit IgG
Secondary antibodies
 Chicken anti-rabbit Alexa 488 (green) Invitrogen A21441 1:500
 Donkey anti-goat Alexa 488 (green) Invitrogen A11055 1:500
 Rabbit anti-mouse Alexa 488 (green) Invitrogen A11059 1:500
 Donkey anti-goat Alexa 555 (red) Invitrogen A21432 1:500
 Goat anti-mouse Alexa 555 (red) Invitrogen A21424 1:500
 Goat anti-rabbit Alexa 555 (red) Invitrogen A21429 1:500
 Hoechst (nuclear staining, blue) Sigma 33258 1:2,000
Isotypes (protein concentration as primary antibody)
 Mouse IgG1 BD Biosciences 550878
 Mouse IgG3 Sigma I3784
 Goat IgG Jackson Labs JACK005-000-0020
 Rabbit serum Dako X0902
Miscellaneous
 Fixation: 10% NBF Sigma HT501128
 Permeabilization: Triton X-100 Acros Organics 422355000
 Blocking: normal donkey serum Jackson Labs JACK017-000-121
 Mounting: ProMount Gold Invitrogen P36930
NBF, neutral buffered formalin.
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Omeprazole (AstraZeneca, cat. no. M130064AB), Step 22, option D only
PBS pH 7.4 w/o CaCl
2
 and MgCl
2
 (Gibco, cat. no. 10010-015)
PE mouse anti-rat CD45 (BD Pharmingen, cat. no. 554878)
Penicillin–streptomycin solution (Cellgro, cat. no. 30-002-CI)
Phenobarbital (Sigma, cat. no. P1636), Step 22, option D only
Phosphoric acid solution for HPLC (H
3
PO
4
) (Fluka, cat. no. 79626), Step 22, 
option F only
P450-Glo CYP1A2 Assay (Promega, cat. no. V8771), Step 22, option D only
QuantiChrom Urea Assay Kit (BioAssay Systems, cat. no. DIUR-500),  
Step 22, option C only
Rat Albumin ELISA Quantitation Set (Bethyl, cat. no. E110-125), Step 22, 
option A only
Rat MAPC (see Box 1 for preparation details)
Tetrabutylammonium hydrogen sulfate (TBA) for HPLC (Acros,  
cat. no. 42010), Step 22, option F only
Tris-phosphate-EDTA buffer 0.8 M (Sigma, cat. no. T3154), Step 22,  
option F only
Trypsin-EDTA 0.05% (Gibco, cat. no. 25300)
Trypsin-EDTA 0.25% (Gibco, cat. no. 25200)
White opaque 96-well plates (Thermo Scientific, cat. no. 15042), Step 22, 
option D only
Xanthobilirubic acid (prepared according to the method of Grünewald  
et al.23), Step 22, option F only
1-Chloro-2,4-dinitrobenzene 99% (CDNB; Acros Organics, cat. no. 16051), 
Step 22, option E only ! cautIon Very toxic to aquatic organisms, may 
cause long-term adverse effects in the aquatic environment. Collect waste 
separately.
2-Mercaptoethanol 50 nM 1,000× (Gibco, cat. no. 31350) 
EQUIPMENT
Analytical nitrogen evaporator (Organomation, cat. no. N-EVAP 11250), 
Step 22, option F only
BioPhotometer 8.5 mm (Eppendorf, cat. no. 6131 23861)
Luminometer (Thermo-Labsystems Fluoroskan Ascent FL)
Liquid chromatograph (Waters, cat. no. 995 photodiode  +  2× Waters,  
cat. no. 515 HPLC pump)
Microplate reader (Bio-Rad, model 3550)
NucleoCounter  +  NucleoCassette (Chemometec)
Spectrophotometer (Shimadzu, cat. no. UV-2101)
Stericup with Millipore Express PLUS 0.22-m filter (Millipore, cat. no. 
SCGP U05 RE) 
REAGENT SETUP
Matrigel-coated plates Store Matrigel (10-ml bottle) at  − 20 °C. It is advis-
able to freeze down Matrigel in separate vials of smaller volume (for example, 
400 µl) to avoid unnecessary freeze-thaw cycles. Matrigel polymerizes at 
room temperature (20 °C), hence it is necessary to thaw the bottle of Matrigel 
on ice and use frozen pipette tips and cryotubes. If thawed too quickly, 
Matrigel will partially polymerize and give rise to clumps.
Thaw one vial (400 µl) of Matrigel slowly on ice. Dissolve 400 µl of 
Matrigel in 20 ml of ice-cold PBS (final concentration 2%) and add 1 ml to 
every well of a 12-well plate or chamber slide. Incubate for at least 30 min at 
37 °C or for 2–3 h at room temperature. Use immediately.
MCDB solution Dissolve one vial of MCDB 201 medium (17.7 g) in  
1,000 ml of Milli-Q water in a flat-bottom Erlenmeyer flask. Stir with a magnetic 
stir bar until completely dissolved (yellow suspension). Measure the pH and 
adjust with NaOH or HCl dropwise until it equals 7.2. Filter the solution us-
ing Stericup filter. The solution can be stored at 4 °C for up to 6 weeks.
0.2% BSA-PBS solution Dissolve 100 mg of BSA in a final volume of 50 ml 
of PBS and filter using Stericup filter to produce a 0.2% BSA-PBS solution. 
Store at 4 °C for several weeks.
0.2% BSA-HCl solution Dilute 200 µl of HCl (stock concentration 2 M) in 
100 ml of distilled water to produce a 4 mM HCl solution. Dissolve 200 mg 
of BSA in a final volume of 100 ml of 4 mM HCl solution. Filter using  
Stericup filter. Store at 4 °C for several weeks.
2% KOH solution Dissolve 2 g of KOH in a final volume of 100-ml metha-
nol to produce a 2% solution. Store at room temperature for several weeks.
60 µM BSA solution Dissolve 198 µg of BSA in 50 ml of hepatic differentia-
tion medium to produce a 60 µM BSA solution. Use immediately.
Activin-A solution Dissolve 5 µg (one vial) in 500 µl of 0.2% BSA-PBS 
to produce a 10-ng µl − 1 solution. Store at 4 °C for 1 week or at  − 80 °C for 
several months.
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Anthrone solution Dissolve 2 mg of anthrone in 1,000-µl H
2
SO
4
 to produce 
a 0.2% solution (yellow color). Use immediately.
Bilirubin solution Dissolve 17.5 mg of bilirubin in 5 ml DMSO to produce 
a 6 mM stock solution. Dissolve 250 µl of stock solution in 50 ml of 60 µM 
BSA solution to produce a final 30 µM bilirubin solution. Use immediately.
BMP4 solution Dissolve 10 µg (one vial) in 1,000 µl of 0.2% BSA-HCl to 
produce a 10-ng µl − 1 solution. Store at 4 °C for 1 week or at  − 80 °C for 
several months.
CDNB solution Dissolve 30.4 mg of CDNB in 5 ml of ethanol to produce  
a 30 mM solution. Use immediately.
Dexamethasone solution Dissolve 100 mg (one bottle) in 1,000 ml of  
distilled H
2
O to produce a 0.25 mM solution. Filter using Millipore Express 
plus a 0.22-µm filter. Store at  − 20 °C for several months.
EGF solution Dissolve 1 mg (one vial) in 5 ml of 0.2% BSA-PBS to produce 
a 200-ng µl − 1 solution. Store at  − 80 °C for several months.
Expansion medium (Table 3) Store at 4 °C for 1 month.
FGF1 solution Dissolve 25 µg (one vial) in 2,500 µl of 0.2% BSA-PBS to 
produce a 10-ng µl − 1 solution. Store at 4 °C for 1 week or at  − 80 °C for 
several months.
FGF2 solution Dissolve 25 µg (one vial) in 2,500 µl of 0.2% BSA-PBS to 
produce a 10-ng µl − 1 solution. Store at 4 °C for 1 week or at  − 80 °C for 
several months.
FGF4 solution Dissolve 25 µg (one vial) in 1,000 µl of 0.2% BSA-PBS to 
produce a 25-ng µl − 1 solution. Store at 4 °C for 1 week or at  − 80 °C for 
several months.
FGF8b solution Dissolve 25 µg (one vial) in 1,000 µl of 0.2% BSA-PBS 
to produce a 25-ng µl − 1 solution. Store at 4 °C for 1 week or at  − 80 °C for 
several months.
Fibronectin solution Dissolve 2 mg in 4,000 µl of PBS to produce a  
500-ng µl − 1 stock solution. Dilute 100 µl of stock solution in 500 ml of PBS 
to produce a final 100-ng ml − 1 solution. Filter using Millipore Express plus 
0.22-µm filter. Store at 4 °C for several weeks.
Follistatin solution Dissolve 25 µg (one vial) in 2,500 µl of 0.2% BSA-PBS 
to produce a 10-ng µl − 1 solution. Store at 4 °C for 1 week or at  − 80 °C for 
several months.
Glycine buffer pH 2.4 Dissolve 15.01 g in 1,000 ml of distilled H
2
O to pro-
duce a 0.2 M glycine solution. Dilute 10 ml of HCl (stock concentration 2 M) 
in 90 ml of distilled water to produce a 0.2 M HCl solution. Dilute  
50 ml of 0.2 M glycine solution with 32.4 ml of 0.2 M HCl solution in  
117.6 ml of distilled H
2
O to produce a final 50 mM glycine buffer of  
pH 2.4. Use immediately.
Glycogen solution Dissolve 1,500 µg of glycogen in 1,500 µl of H
2
O to  
produce a 1-mg ml − 1 solution. Store at  − 20 °C for several months.
GSH solution Dissolve 0.384 mg of GSH in 1 ml of phosphate buffer to 
produce a 1.25 mM solution. Use immediately.
table 3 | Expansion medium (500 ml).
component Volume (ml) Final concentration
DMEM-low glucose 270
MCDB 200
FBS 10 2%
ITS 5 1×
LA-BSA 5 1×
Penicillin-streptomycin 5 1×
l-Ascorbic acid (10 mM) 5 100 nM
PDGF-BB (10 µg ml − 1) 0.5 10 ng ml − 1
Dexamethasone (0.25 mM) 0.1 50 nM
LIF (107 units ml − 1) 0.05 103 units ml − 1
EGF (200 µg ml − 1) 0.025 10 ng ml − 1
EGF, epidermal growth factor; ITS, insulin-transferrin-selenium; LA-BSA, linoleic acid–BSA;  
LIF, leukemia inhibitory factor

.
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Hepatic differentiation medium (Table 4) Store at 4 °C for 1 month.
HGF solution Dissolve 25 µg (one vial) in 2,500 µl of 0.2% BSA-PBS to produce 
a 10-ng µl − 1 solution. Store at 4 °C for 1 week or at  − 80 °C for several months.
l-Ascorbic acid solution Dissolve 1.45 g in 500 ml of PBS to produce a 10 mM 
solution. Stir with a magnetic stir bar for 10–20 min in the dark and filter using 
Stericup filter. Store at  − 20 °C for several months.
Omeprazole solution Dissolve 40 mg (one vial) of omeprazole in 10 ml of 
0.9% NaCl to produce a 4-mg ml − 1 (11.58 mM) solution. Store at  − 20 °C for 
several months.
Platelet-derived growth factor BB solution (PDGF-BB) Dissolve 50 µg 
(one vial) in 5 ml of 0.2% BSA-HCl to produce a 10-µg ml − 1 solution. Store 
at  − 80 °C for several months.
Phenobarbital solution Dissolve 5 g of phenobarbital in 21.52 ml of PBS to 
produce a 1 M stock solution. Store at  − 20 °C for several months. Dilute  
500 µl of 1 M stock solution in 9.5 ml of PBS to produce a final 50 mM  
working solution. Store at 4 °C for several weeks.
Phosphate buffer pH 6.5 Dissolve 1.7 g of KH
2
PO
4
 in 100 ml of PBS to 
produce a 125 mM solution. Measure the pH and add drops of KOH until 
the pH is 6.5. Use immediately.
Wnt3a solution Dissolve 5 µg (one vial) in 500 µl of 0.2% BSA-PBS to produce 
a 10-ng ml − 1 solution. Store at 4 °C for 1 week or at  − 80 °C for several months.
EQUIPMENT SETUP
Microplate reader (albumin secretion, Step 22A, and urea production, 
Step 22C only) Use dual optical photometric settings with 450 nm as the first 
wavelength (samples) and 655 nm as the second wavelength (background).
Spectrophotometer (glycogen storage, Step 22B only) Use the quantitative 
mode with a wavelength of 620 nm. Create a standard curve with 12 readings 
(six readings in duplicate), entering the micrograms of glycogen.
Spectrophotometer (GST activity, Step 22E only) Use the time-course mode 
with a wavelength of 340 nm. Set the number of readings to 7, with a 1-min 
interval.
Luminometer (cytochrome activity, Step 22D only) Start with a shaking 
step for 1 min at 300 r.p.m., followed by detection using the kinetic mode.  
Set the number of readings to 11, with a 2-min interval.
High-pressure liquid chromatography (bilirubin conjugation, Step 22F 
only) Create solvent A (66 ml of methanol  +  39 ml of Milli-Q water  +   
160 µl of TBA, brought to pH 7.6 with H
3
PO
4
) and solvent B (75 ml of 
methanol  +  16 ml of Milli-Q water  +  10 ml of ethanol  +  140 µl of TBA  +  
150 µl of Tris, brought to pH 7.5 with H
3
PO
4
) and connect both bottles to 
a HPLC pump. Set a continuous solvent flow rate of 1 ml min − 1. Start with 
100% solvent A–0% solvent B mixture and gradually change to 0% solvent 
A–100% solvent B mixture by minute 11. Continue the same settings for  
6 min until minute 17.
proceDure
seeding undifferentiated rMapcs ● tIMInG 1 h (1 day before differentiation)
1| Grow and isolate rMAPCs; for further details, see box 1 (ref. 1). Grow cells in 10-cm dishes until they are  > 80% confluent.
2| Aspirate the expansion medium and rinse the dishes with PBS.
3| To detach the cells, add 1 ml of trypsin 0.25%. Increase the dislodgment of cells by patting the plates gently. Check  
using a microscope whether all cells are detached.
 crItIcal step Avoid overexposure to trypsin, as this is harmful to the cells. Limit the incubation time to less than 2 min, 
and do not incubate at 37 °C during trypsinization.
4| Block trypsin with 2 ml of expansion medium per dish.
5| Aspirate cells in a centrifuge tube and quantify using NucleoCounter.
6| Centrifuge at 700g for 6 min.
7| Remove the supernatant and resuspend 106 cells in 7.5 ml of expansion medium.
8| Remove 2% Matrigel solution from wells of a 12-well Matrigel-coated plate (prepared as detailed in REAGENT SETUP).
9| Add 1.5 ml of cell suspension to every well (200,000 cells per well, density 52,600 cells cm − 2).
10| Store in a 5% O2–5.8% CO2–37 °C incubator until cells become 80–90% confluent (usually after 12–24 h).
 crItIcal step rMAPCs need to be confluent when initiating differentiation cultures, hence it is important not to start  
the first step of differentiation too quickly after plating the cells.
Hepatocyte differentiation protocol ● tIMInG 20 days
11| Remove the expansion medium, rinse wells with PBS.
table 4 | Hepatic differentiation medium (500 ml).
component Volume (ml) Final concentration
DMEM-low glucose 285
MCDB 200
Penicillin-streptomycin 5 1×
l-Ascorbic acid (10 mM) 5 100 nM
Dexamethasone (0.25 mM) 2 1 µM
ITS 1.25 0.25×
LA-BSA 1.25 0.25×
2-Mercaptoethanol (50 mM) 0.5 50 µM
ITS, insulin-transferrin-selenium; LA-BSA, linoleic acid–BSA.
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 crItIcal step Ensure that floating cells are washed away carefully because they may have a negative impact on the  
first days of differentiation.
12| Add 1.5 ml of differentiation medium containing 15 µl of Activin-A solution (final concentration 100 ng ml − 1) and 7.5 µl 
of Wnt3a solution (final concentration 50 ng ml − 1) per well. Store in a 21% O2–5.8% CO2–37 °C incubator until day 2.
13| On day 2, remove 950 µl of medium and add 1,000 µl of differentiation medium containing 10 µl of Activin-A solution 
and 5 µl of Wnt3a solution. Store in a 21% O2–5.8% CO2–37 °C incubator until day 4.
14| On day 4, remove 950 µl of medium and add 1,000 µl of differentiation medium containing 10 µl of Activin-A solution 
and 5 µl of Wnt3a solution. Store in a 21% O2–5.8% CO2–37 °C incubator until day 6.
15| On day 6, remove all medium. Rinse with PBS. Add 1.5 ml of differentiation medium containing 1.5 µl of FGF2  
solution (final concentration 10 ng ml − 1) and 7.5 µl of BMP4 solution (final concentration 50 ng ml − 1). Store in a 21% 
O2–5.8% CO2–37 °C incubator until day 8. If desired, retain the samples for further analysis (see Step 22).
16| On day 8, remove 950 µl of medium and add 1,000 µl of differentiation medium containing 1 µl of FGF2 solution and  
5 µl of BMP4 solution. Store in a 21% O2–5.8% CO2–37 °C incubator until day 10.
17| On day 10, remove all medium. Rinse with PBS. Add 1.5 ml of differentiation medium containing 3 µl of FGF1 solution 
(final concentration 20 ng ml − 1), 1.5 µl of FGF8b solution (final concentration 25 ng ml − 1) and 0.6 µl of FGF4 solution  
(final concentration 10 ng ml − 1). Store in 21% O2–5.8% CO2–37 °C incubator until day 12. If desired, retain samples for 
further analysis (see Step 22).
18| On day 12, remove 950 µl of medium and add 1,000 µl of differentiation medium containing 2 µl of FGF1 solution,  
1 µl of FGF8b solution and 0.4 µl of FGF4 solution. Store in a 21% O2–5.8% CO2–37 °C incubator until day 14.
19| On day 14, remove all medium. Rinse with PBS. Add 1.5 ml of differentiation medium containing 3 µl of HGF  
solution (final concentration 20 ng ml − 1) and 15 µl of Follistatin-288 solution (final concentration 100 ng ml − 1). Store in 
21% O2–5.8% CO2–37 °C incubator until day 16. If desired, retain the samples for further analysis (see Step 22).
20| On day 16, remove 950 µl of medium and add 1,000 µl of differentiation medium containing 2 µl of HGF solution and  
10 µl of Follistatin-288 solution. Store in a 21% O2–5.8% CO2–37 °C incubator until day 18.
21| On day 18, remove 950 µl of medium and add 1,000 µl of differentiation medium containing 2 µl of HGF solution and  
10 µl of Follistatin-288 solution. Store in a 21% O2–5.8% CO2–37 °C incubator until day 20.
22| On day 20, analyze the hepatocyte characteristics. A single test cannot effectively evaluate the hepatocyte characteristics 
of MAPC progeny. It is important to assess the gene expression profile, as well as protein synthesis and functional analysis, of 
the cells. This can be carried out in a number of ways: real-time RT-qPCR (box 2), immunocytochemistry (box 3), ultrastruc-
tural evaluation of hepatocyte cells (electron microscopy, data not shown) or by functional analysis (options A–F) of albumin 
secretion (option A), glycogen storage as per the spectrophotometrical method of Seifter et al.24 (option B), urea production 
(option C), determination of cytochrome P450 subtype Cyp1a1/1a2 activity (option D), determination of GST activity according 
to the spectrophotometrical method of Habig et al.25 (option E) and/or bilirubin conjugation by HPLC according to the method 
of Muraca and Blanckaert26 (option F).
(a) albumin secretion ● tIMInG 5 h
 (i) Collect the supernatant from desired time points in 1.5-ml tubes.
 (ii)  Centrifuge at  > 8,000g for 1 min.  
 pause poInt Use immediately or store at  − 20 °C.
 (iii)  Proceed as indicated by the manufacturer (step 1, capture the antibody for 60 min; step 2, use the blocking solution 
for 30 min; step 3, dilute the samples at 1:40 and use the standard solution for 60 min; step 4, use the HRP detection 
antibody (part of the Rat Albumin ELISA Quantitation Set (see REAGENTS)) for 60 min; step 5, TMB (TMB-peroxidase 
solution; part of the ELISA Starter Accessory Kit (see REAGENTS)) for 15 min; step 6, H2SO4).
 (iv)  Read the OD on a microplate reader at a wavelength of 450 nm (specific for TMB). Determine the average OD of  
duplicate wells and subtract the ODmedium from all samples.
 (v)  Create a four-parameter standard curve (y  =  ax3  +  bx2  +  cx  +  d) by plotting ODstandard on the x axis and log(Concstandard) 
on the y axis (log scale is used to ensure that no negative values are obtained).
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 (vi) Calculate log(Concsample) by using ODsample in the standard curve equation.
 (vii)  To obtain the final concentration, calculate 10 to the power log(Concsample) and multiply by 40 (dilution correction). 
Results are depicted as ng ml − 1. 
 Standard curve: y ax bx cx d= + + +3 2
 Albumin OD OD ODsample sample sample samp= + +40 10 3 2* ^[ *( ) *( ) *(a b c le) ]+ d
(b) Glycogen storage ● tIMInG 3–4 h
 (i)  At the desired time point, remove the supernatant from the wells of interest and rinse with PBS. If required,  
different concentrations of glucose in the medium can be added, as this will influence the amount of stored  
glycogen (see Anticipated results).
 (ii) Add 500 µl of trypsin 0.05% until the cells detach.
 (iii) Add 1,000 µl of medium/supernatant to block trypsin.
 (iv) Scrape the bottom of wells with the tip of a 1,000-µl pipette or cell scraper to ensure that all cells are collected.
 (v) Pipette the cell suspension in a 1.5-ml tube and centrifuge at 2,100g for 6 min.
 (vi)  Remove the supernatant and resuspend the pellet in 200 µl of distilled H2O to create a homogenous cell suspension. 
 pause poInt Samples can be stored at −80 °C for several weeks.
 (vii)  Pipette 60 µl of the cell suspension in a 1.5-ml tube with a screw top. Store the remaining cell suspension at  − 20 °C  
for protein analysis.
 (viii) Add 240 µl of 33% KOH solution to the tube and screw the top tightly.
 (ix) Heat the tube to 100 °C in heating block for 20 min.
 (x) Cool the tube in ice water.
 (xi) Pipette 125 µl of the sample-KOH suspension in a 15-ml tube in duplicate.
 (xii) Pipette 875 µl of H2O to each 15-ml tube (total volume 1 ml).
 (xiii)  Prepare the standard curve by bringing 0, 1, 2, 3, 5 and 10 µl of a 1-mg ml − 1 glycogen solution to a total volume  
of 1 ml with H2O in a 15-ml tube.
 (xiv)  Slowly pipette 2 ml of yellow anthrone solution to all tubes. 
! cautIon Adding H2SO4 to H2O results in a strong exothermic reaction, which may spatter if added too quickly.  
The bottom of the tube will heat up and may cause burns. Wear protective glasses, clothes and gloves.
 (xv)  Vortex the tubes. The color of the standard curve changes from yellow to dark green. Because of the reaction with glyco-
gen, the solution is slightly viscous (the darker the color, the higher the viscosity, and the higher the glycogen content).
 (xvi) Leave for 10 min, vortex again.
 (xvii)  Read the OD at 620 nm (1 ml per cuvette) starting with a standard curve with known content (0–1–2–3–5–10 µg).  
The readout of the samples provides you with the glycogen content in the tube (µg).
 (xviii)  Multiply the glycogen content by 40 (correction for KOH and H2O–anthrone dilution) to obtain the glycogen concen-
tration in the primary cell suspension (µg ml − 1) 
 Standard curve: y ax b= +
 
Glycogen ODsample sample= +40*[ * ]a b
 (xix)  To compare samples, quantify the total protein content by using the spectrophotometrical method of Bradford et al.27. 
Alternative methods can be used.
 Box 3 | IMMUNoCYToCHEMISTRY EVALUATIoN oF PRoTEIN ExPRESSIoN 
  (i) Fix the cells in wells using 10% neutral buffered formalin (NBF)
 (ii)  Permeabilize cells with PBST (0.2% Triton in PBS) containing 3–5% serum of the secondary antibody for blocking. Alternatively, 
donkey serum can be used.
(iii) Incubate overnight at 4 °C with primary antibodies and the respective isotypes (diluted in PBST containing 3–5% serum).
 (iv) Incubate with secondary antibodies and nuclear counter stain
  (v) Mount slides and store at 4 °C in the dark
 (vi) Possible combinations are (items in boldface type are detailed in Fig. 4)
     Undifferentiated rMAPCs: oct4 + /Foxa2 + /sox7 + /sox17 + 
     Hepatoblast and fetal hepatocyte stage: Oct4 − /Afp + /Alb + , Krt18 + 
     More mature hepatocyte-like cells: afp − /alb + , Aat + , Mrp2 + , pepck + 
     Liver-enriched transcription factors: Hnf4α + 
 Adapted from Sancho-Bru et al.28.
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 (xx)  Divide the glycogen concentration (µg ml − 1) by the protein concentration (mg ml − 1). The results can be displayed  
as µg glycogen per mg protein or as nmol glucose per mg protein (dividing the glycogen concentration by the  
molecular mass of glucose, 180.16 g mol − 1).
(c) urea production in relation to ammonia ● tIMInG 1 h plus 24 h incubation before assay
 (i) At the desired time point, remove the supernatant from the wells of interest and wash the wells with PBS.
 (ii)  Add 1,000 µl of differentiation medium containing 0 or 1 mM of ammonium bicarbonate (NH4HCO3). Use one well  
containing 1 mM of sodium bicarbonate (NaHCO3) as control for increased alkalosis. 
 crItIcal step Do not use NH4Cl, as this will make the medium slightly more acidic. Acidosis inhibits the production 
of urea. If NH4HCO3 is used, always use 1 mM of NaHCO3 in the control well to normalize for the relative alkalosis.
 (iii)  After 24 h, collect the supernatant in a 1.5-ml tube and replace with normal differentiation medium.  
 pause poInt Use immediately or store samples at  − 20 °C until further use.
 (iv)  Transfer 50 µl of supernatant in duplicate to a transparent 96-well plate.
 (v)  Dilute the internal standard to 1:10 with H2O to a final concentration of 5 µg ml − 1. Transfer 50 µl of internal standard 
in duplicate to a transparent 96-well plate.
 (vi) Transfer 50 µl of fresh hepatic differentiation medium in duplicate to a transparent 96-well plate.
 (vii) Mix an equal volume of QuantiChrom Urea Assay Kit Reagents A and B.
 (viii) Add 200 µl of reagent mix to every well.
 (ix) Transfer 50 µl of supernatant in duplicate to a transparent 96-well plate.
 (x)  Incubate at room temperature for 50 min. 
 crItIcal step Unlike with classical ELISA, there is no termination of the reaction. Ensure that absorbance is read 
no later than 50 min after adding the reagents.
 (xi) Read the absorbance at 450 nm.
 (xii)  Subtract the result of the medium from every sample. Divide by absorbance of the internal standard and multiply by  
5 to obtain the final result, which is given in µg ml − 1. 
 Urea Abs Abs Abssample sample medium internal standard= −[( )/ ]*5
(D) cytochrome p450 activity ● tIMInG 6 h plus 24 h incubation before assay
 (i)  To study the induction at a desired time point, add 10 µM of omeprazole (1.3 µl of stock solution) or 500 µM of phe-
nobarbital (10 µl of working solution) to the differentiation medium 24 h before the assay to the wells to be evalu-
ated. As omeprazole is stable only for 12 h, repeat the process 12 h before the assay. Always use one well as negative 
control by adding 1.3 or 10 µl of PBS, respectively, to the differentiation medium.
 (ii)  At the desired time point, remove the supernatant and rinse well with PBS. 
 crItIcal step Wash well because omeprazole and phenobarbital degradation products may interfere with the  
luciferase assay.
 (iii)  Pipette 400 µl of hepatic differentiation medium into every well, including one well without cells (background luminescence).
 (iv) Add 8 µl of luminogenic substrate (Luciferin-ME specific for Cyp1a1/1a2) to every well.
 (v) Store in 21% O2–5.8% CO2–37 °C incubator for 4 h.
 (vi) Collect supernatant, replace with 500 µl of medium (to keep the cells from drying).
 (vii) Transfer 50 µl of supernatant to a white opaque 96-well plate in triplicate.
 (viii) Add 50 µl of Luciferin Detection Reagent to every well.
 (ix)  Read the luminescence (11 consecutive time points with a 2-min interval, total 22 min). In the meantime, remove all 
medium and add 500 µl of trypsin 0.05% to the wells until the cells detach.
 (x) Add 1,000 µl of the medium or supernatant to block the trypsin.
 (xi) Scrape the bottom of wells with the tip of a 1,000-µl pipette or cell scraper to ensure that all cells are collected.
 (xii) Count the cells.
 (xiii)  Determine the average signal of 11 time points (Luminsample) and subtract Luminmedium from the samples to obtain  
the net signal.
 (xiv)  To normalize for the different cell number, multiply the net signal by 106 and divide by the number of cells. Results are 
now depicted as cytochrome activity per million cells. As the results are presented in relative light units, scaling can 
be performed easily. In induction studies, results can also be depicted as fold increase. 
 Cyp1a2 activity Lumin Lumin csample sample medium= −1 000 000, , *( )/ ell number
 
Increase activity activity or activity acday day induction= 20 14/ / tivityno induction
(e) Gst activity ● tIMInG 1 h
 (i) At the desired time point, remove the supernatant from the wells of interest and rinse with PBS.
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 (ii) Add 500 µl of trypsin 0.05% until the cells detach.
 (iii) Add 1,000 µl of medium/supernatant to block trypsin.
 (iv) Scrape the bottom of the wells with the tip of a 1,000-µl pipette to ensure that all cells are collected.
 (v) Collect the cell suspension in a 1.5-ml tube and centrifuge at 2,100g for 6 min.
 (vi)  Remove the supernatant and resuspend the pellet in 300 µl of PBS to create a homogenous cell suspension. 
 pause poInt Samples can be stored at −80 °C for several weeks.
 (vii) Add 600 µl of GSH solution and 25 µl of CDNB solution to the cuvette.
 (viii) Add 125 µl of cell suspension to the cuvette, mix well. Use 125 µl of PBS as negative control.
 (ix)  Read the absorbance at 340 nm (formation of the CDNB-GSH conjugate) for 6 min with a 1-min interval (seven readings).
 (x)  Only the linear part of the reaction should be used to calculate the GST activity. Therefore, subtract the absorbance  
at minute 2 (Abs2min) from the absorbance at minute 6 (Abs6min) to define the difference in absorbance (∆Abs).
 (xi) Subtract ∆AbsPBS from ∆Abssample.
 (xii)  Divide ∆Abs by 4 (∆Abs per minute) and divide by the extinction coefficient of CDNB, namely, 9.6 mM − 1 (results  
depicted as µM per min GSH-CDNB). Multiply by 750 to obtain the activity as nmol per min GSH-CDNB 
 ∆Abs Abs Abssample PBS sample PBS sample PBS/ / min / min= −6 2
 
Total GST activity ml Abs Abs msample sample PBS= −750 4 9 6*[( )/ ]/ .∆ ∆ M−1
 (xiii)  To compare samples, quantify the total protein content using either the spectrophotometrical method of Bradford27 or 
alternative methods.
 (xiv)  Divide the amount of GSH-CDNB by the protein concentration (mg ml − 1). The results can be displayed as nmol  
GSH-CDNB per mg protein per min.
(F) bilirubin conjugation ● tIMInG 2–3 h (up to 33 h of sample harvesting)
 (i) At the desired time point, remove the supernatant from the wells of interest and rinse with PBS.
 (ii)  Add 1,000 µl of bilirubin solution to the wells of interest and to one empty well (first negative control). Add 1,000 µl 
of 60-µM BSA solution to one well containing cells as a second negative control. 
 crItIcal step As bilirubin is light sensitive, it is important to work in a dim-light environment.
 (iii)  Harvest the supernatant at different time points (6, 12, 24 and 33 h). 
 pause poInt Samples can be stored at  − 80 °C for a maximum of 1 month.
 (iv) Place 500 µl of sample in 10-ml glass tubes with ground-glass stoppers.
 (v) Add 60 mg of ascorbic acid and 2 mg of disodium EDTA.
 (vi) Add 2 ml of internal standard solution (xanthobilirubinic acid methyl ester 2 µg ml − 1).
 (vii) Add 6 ml of 2% KOH solution.
 (viii) Vortex and incubate the mixture for 60–90 s.
 (ix) Add 6 ml of chloroform and 12 ml of glycine buffer.
 (x) Shake briefly and centrifuge at 1,000g for 10 min.
 (xi) Transfer the organic phase (bottom chloroform layer) to a dry 10-ml conical tube.
 (xii)  Evaporate at 50 °C under a N2 stream. 
 pause poInt The residue can be stored at  − 20 °C for 2 weeks.
 (xiii) Dissolve the residue in 10 µl of chloroform and 100 µl of DMSO shortly before analysis, shake briefly.
 (xiv)  Inject 10 µl into the liquid chromatograph. Separate the pigments by eluting the column at a solvent rate of  
1 ml min − 1 with a linear gradient over 17 min. Monitor the absorbance at 436 nm.
 (xv)  In case of doubt (for example, heme interference in control samples), analyze the different peaks by using spectrum 
analysis. The internal standard has a peak emission at 413 nm, bilirubin around 450 nm and heme at 405 nm.
 (xvi)  Normalize the equation for different volumes (volume internal standard 2 ml, volume of the sample 0.5 ml) and com-
pare with the concentration of the internal standard (2 µg ml − 1). To carry this out, multiply the equation of the areas 
by 8 and by the pigment-dependent factor F. Depict results as µg ml − 1. The results can also be depicted as % decrease 
in unconjugated bilirubin or % conjugation of bilirubin into mono/diconjugate. 
 Bilirubin pigment concentration pigment IS= 8* * /F A A
where Apigment is the peak area of the pigment, AIS the peak area of internal standard, F the pigment-dependent factor, 
unconjugated bilirubin F  =  1.102, bilirubin monoconjugate F  =  1.279, bilirubin diconjugate F  =  1.329.
● tIMInG
Steps 1–10, Seeding undifferentiated rMAPCs: 1 h (1 day before differentiation)
Steps 11–21, Hepatocyte differentiation: 20 days
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Step 22 option A, Albumin secretion: 5 h
Step 22 option B, Glycogen storage: 
3–4 h
Step 22 option C, Urea production: 1 h 
(24-h incubation before assay)
Step 22 option D, Cytochrome P450 
activity: 6 h (24-h incubation before 
assay)
Step 22 option E, GST activity: 1 h
Step 22 option F, Bilirubin conjugation: 
2–3 h (up to 33 h of sample harvesting)
antIcIpateD results
To ensure that differentiation has been performed correctly, it is important to monitor the acquisition of the correct  
phenotype for each of the embryonic stages of liver differentiation. Morphological changes can be visualized easily with 
bright field microscopy (Fig. 2).
As indicated in the detailed protocol section, samples are taken for RNA analysis and functional assays at 6, 10, 14 
and 20 days. No single gene or test can efficiently identify the phenotype acquired by the stem cell progeny. In boxes 2 
and 3, an extended list of assays that allow identification 
of hepatocyte-like cell differentiation is summarized.
Gene expression profile of stem cell progeny
Gene expression analysis can be performed on days 0, 6, 
10, 14 and 20 of differentiation to identify the correctly 
directed differentiation of the cells. Step 1 of the differen-
tiation protocol clearly induces the expression of PS/ME/DE 
genes such us Gsc, Mixl1, Cxcr4 and Tm4sf2 (Fig. 3a).  
After stimulating first with BMP4 and FGF2 (Step 2), and 
then with FGF1, 4 and 8 (Step 3), those genes that are  
typically expressed in hepatoblasts and immature hepato-
cytes begin to be expressed (Afp, Ttr, Krt19, Alb, Aat)  
(Fig. 3b). Step 4 induces the maturation of immature liver 
cells to a hepatocyte-like phenotype, which is revealed by 
the increased expression of genes expressed perinatally  
such as Tat, G6pc, Cyp450 and Factor V (Fig. 3c). Besides 
commitment to the liver, a fraction of cells is also directed 
to other endodermal (Pdx1, Cdx2, Tmprss2) and mesodermal 
cells (Sm22, α-Sma, Cnn1, Nkx2.5, Tbx5).
Immunocytochemistry analysis shows that at day 0  
nearly 100% of the cells are Oct4 +  Sox7 +  Sox17 +  Foxa2 +  
Day 1
Day 8
Cobblestone cells
Clusters of
round cells
Day 18 Day 20
Day 12 Day 14
Clusters of round,
densely packed cells
Day 2 Day 4
Figure 2 | Bright field microscopy of 
rMAPC progeny during liver differentiation. 
Undifferentiated rMAPCs are round to spindle 
shaped. On plating at high density they become 
more triangular and square (days 2–4). During 
the later stages of differentiation, clusters of 
round, densely packed cells appear together with 
more cobblestone-like cells. By day 20, the cells 
are more rectangular with clear nuclei (scale bar,  
100 µm).
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Figure 3 | RT-qPCR analysis of rMAPC progeny during liver differentiation, 
depicted as deltaCT compared with Gapdh (DeltaCT  =  CTgene  −  CTGAPDH). The 
lower the DeltaCT value, the higher the expression level. (a) Induction of 
primitive streak/mesendoderm/definitive endoderm genes. (b) Induction 
of early liver-specific genes. (c) Induction of more mature liver-specific 
genes.
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(Fig. 4a). At day 20, the differenti-
ated stem cell progeny is a mixture of 
immature cells that coexpress Alb and 
Afp, and more mature cells expressing 
Alb but no longer Afp. Approximately 
80% of differentiated cells expressed 
Afp, whereas expression of Alb was 
variable and patchy (range 5–30% 
Alb + ). A small fraction of the prog-
eny is Krt18 +  and Pepck +  (Fig. 4b). 
Electron microscopy studies of the 
differentiated population reveal cells 
with immature characteristics, together 
with cells with more mature hepatocyte 
characteristics (data not shown).
Hepatocytes exert a number of 
synthetic, storage and detoxifying 
functions. Thus, functional assays al-
low a more stringent characterization 
of stem cell progeny. As shown in 
Figure 5a,b, differentiated cells produce albumin and store glycogen (in response to the glucose level in the  
medium). Moreover, stem cell progeny secrete urea, which is enhanced by the incubation with NH4HCO3 (Fig. 5c),  
and have inducible cytochrome  
activity, as incubation of cells with 
omeprazole (as well as with pheno-
barbital, a well-known inducer  
of Cyp1a2) results in increased  
activity (Fig. 5d). Finally, hepato-
cyte-like cells are able to detoxify  
as demonstrated by GST activity  
(Fig. 5e) and bilirubin conjugation 
(Fig. 5f).
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Figure 4 | Immunocytochemistry analysis.  
(a) Undifferentiated rMAPCs are positive 
for Oct4, Sox7, Sox17 and Foxa2 (scale bar, 
100 µm). (b) Day 20 rMAPC progeny express 
albumin (green), α-fetoprotein (red) and  
to a lesser extent Krt18 and Pepck (scale bar, 
50 µm).
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Figure 5 | Functional assays on rMAPC progeny 
(one representative experiment) during liver 
differentiation. (a) Albumin secretion;  
(b) glycogen storage in relation to low and high 
concentrations of glucose; (c) urea production 
in relation to ammonia; (d) rMAPC d 20 progeny 
Cyp1a2 activity, inducible with omeprazole; 
(e) GST activity; and (f) rMAPC d 20 progeny 
bilirubin conjugation.
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